22 FEB. 2025
The LFB’s EMABling© platform
For monoclonal antibodies with high cytotoxic activity
EMABling® enables the development and production of recombinant monoclonal antibodies with high cytotoxic activity (increased ADCC), thanks to an improved glycosylation profile. Research conducted by LFB’s teams in this field has been based on the study of the relationship between the structure and function of monoclonal antibodies, and in particular the importance of post-translational modifications for their functional activity (role of glycans).
For the production of your recombinant monoclonal antibodies, we offer our proprietary EMABling© platform based on your project and your needs. Contact us to learn more about its advantages for the production of your antibodies and cell lines.
Two complementary services for your antibody production
Feasibility study
We generate stable pools of recombinant YB2/0-E cells (EMABling® platform), deliver purified IgG to the research stage for analysis, and create CHO versions of the recombinant product for comparative studies.
This intermediary service in cell line development allows you to evaluate and choose the technological platform best adapted to your production, while optimising risk management and cost control.
Complete cell line development
We can assist you with all the steps of cell line development, with a focus on delivering a recombinant YB2/0-E line that can generate mAbs with high cytotoxic activity and low fucose content, at a good level of productivity.
Find out more about our cell line and cell bank development capabilities, or contact us to discuss your biotechnology project.
A technology patented in Europe and the United States to guarantee innovative solutions.
